Faron Pharmaceuticals - Innovative medical solutions (Part 2)

“In my opinion, the idea goes horribly wrong if this is compared to a typical underperforming company, where costs are cut and ways to survive are sought.”

This net result of 130 million euros in the red over the last five years does not speak of a very successful company (2021-2025).

Of course, I understand the point that it is good to get the best talent involved, and they don’t come for free. When one follows Faron’s activities, it is easy to see that money is spent as if this were Nokia or Nordea or something similar. And it’s good to splurge if you trust that the next share issue will be launched when the money runs out. So far, this has worked, but it’s no guarantee for the future. That’s why I would hope that money would primarily be used to advance research, because the information coming from there will ultimately determine how this all turns out, not so much how many top professionals sit on the board.

5 Likes